Dr. D'Adamo is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Office
450 Brookline Ave
Boston, MA 02215Phone+1 617-632-5204Fax+1 617-632-3408
Education & Training
- Memorial Sloan Kettering Cancer CenterFellowship, Hematology and Medical Oncology, 1999 - 2002
- Icahn School of Medicine at Mount Sinai/Mount Sinai HospitalResidency, Internal Medicine, 1997 - 1999
- New York University School of MedicineClass of 1997
Certifications & Licensure
- NY State Medical License 1998 - 2022
- MA State Medical License 2011 - 2014
Clinical Trials
- Doxorubicin Hydrochloride and Alvocidib in Treating Patients With Metastatic or Recurrent Sarcoma That Cannot Be Removed By Surgery Start of enrollment: 2004 Oct 01
Publications & Presentations
PubMed
- 22 citationsPhase II randomised discontinuation trial of brivanib in patients with advanced solid tumoursRobin L. Jones, Mark J. Ratain, Peter J. O'Dwyer, Lillian L. Siu, Jacek Jassem
European Journal of Cancer. 2019-10-01 - 11 citationsA Phase II Trial of Sorafenib and Dacarbazine for Leiomyosarcoma, Synovial Sarcoma, and Malignant Peripheral Nerve Sheath TumorsD. R. D'Adamo, Mark A. Dickson, Mary Louise Keohan, Richard D. Carvajal, Martee L. Hensley
The Oncologist. 2019-06-01 - Eribulin versus dacarbazine in patients with leiomyosarcoma: subgroup analysis from a phase 3, open-label, randomised study.Jean-Yves Blay, Patrick Schöffski, Sebastian Bauer, Anders Krarup-Hansen, Charlotte Benson
British journal of cancer. 2019-05-09
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence: